NLRP3 and atherosclerosis: As an anti‐inflammatory drug, colchicine mainly inhibits the inflammatory response in atherosclerosis in three ways, as follows: 1 damping P2X7‐induced K+ channel opening and reduce K+ efflux; 2 restraining microtubule synthesis and reducing the assembly of NLRP3 inflammasomes and ASC and the formation of NLRP3 inflammatory complex; 3 inhibiting caspase‐1 conversion pro‐IL‐1β into the active form of IL‐1β.